ProCE Banner Activity

CME

Optimizing NSCLC Treatment: Potential of ADCs Targeting HER2, HER3, and TROP-2

Video

On-demand webcast of expert faculty presentation and case discussion on the potential of antibody–drug conjugates that target HER2, HER3, and TROP-2 to optimize treatment outcomes of patients with non-small-cell lung cancer. 

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: February 05, 2024

Expiration: February 04, 2025

Share

Faculty

Rebecca S. Heist

Rebecca S. Heist, MD, MPH

Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Stephen V. Liu

Stephen V. Liu, MD

Associate Professor of Medicine
Director, Thoracic Oncology
Head, Developmental Therapeutics
Georgetown University
Washington, DC

Helena Yu

Helena Yu, MD

Associate Attending
Research Director of Thoracic Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Target Audience

This program is intended for physicians and other healthcare professionals caring for lung cancer patients.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Non-Small Cell Lung Cancer (NSCLC).

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Provide a detailed understanding of the role of HER2, HER3, and TROP-2; rationale for targeting with antibody–drug conjugates; and pathological considerations in NSCLC

  • Apply new data and evolving science specific to antibody–drug conjugates into clinical practice to expand treatment options and improve outcomes for patients with NSCLC malignancies

  • Plan individualized treatment strategies, incorporating novel HER2-, HER3-, or TROP-2–targeted antibody–drug conjugate combination strategies as appropriate for patients with NSCLC

  • Develop individualized strategies involving the patient care team for the early identification and management of antibody–drug conjugate–associated adverse events

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Rebecca S. Heist, MD, MPH

Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Rebecca S. Heist, MD, MPH: consultant/advisor: AbbVie, AstraZeneca, Claim Therapeutics, Daiichi Sankyo, EMD Serono, Lilly, Novartis, Regeneron, Sanofi; researcher (paid to institution): AbbVie, Agios, Corvus, Daiichi Sankyo, Erasca, Lilly, Mirati, Novartis, Turning Point.

Stephen V. Liu, MD

Associate Professor of Medicine
Director, Thoracic Oncology
Head, Developmental Therapeutics
Georgetown University
Washington, DC

Stephen V. Liu, MD: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Catalyst, Daiichi Sankyo, Eisai, Elevation Oncology, Genentech/Roche, Gilead, Guardant Health, Janssen, Jazz Pharma, Merck, Merus, Mirati, Novartis, Regeneron, Sanofi, Takeda, Turning Point Therapeutics; researcher: AbbVie, Alkermes, Elevation Oncology, Ellipses, Genentech, Gilead, Merck, Merus, Nuvalent, RAPT, Turning Point Therapeutics.

Helena Yu, MD

Associate Attending
Research Director of Thoracic Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Helena Yu, MD: consultant/advisor/speaker: Amgen, AstraZeneca, Black Diamond, Daiichi Sankyo, Janssen, Taiho, Takeda; researcher: AstraZeneca, Black Diamond, Cullinan, Daiichi Sankyo, Erasca, Janssen, Novartis, Pfizer. 

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 05, 2024, through February 04, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.